Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 291Carcinoma, Non-Small-Cell Lung 206Prostatic Neoplasms 158Lung Neoplasms 93Stomach Neoplasms 69Neoplasms 69Head and Neck Neoplasms 60Squamous Cell Carcinoma of Head and Neck 56Neoplasm Metastasis 50Esophageal Neoplasms 49Ovarian Neoplasms 39Pancreatic Neoplasms 26Sarcoma 23Carcinoma, Ovarian Epithelial 20Urinary Bladder Neoplasms 19Unspecified Adult Solid Tumor, Protocol Specific 19Breast Neoplasms, Male 17Adenocarcinoma Of Esophagus 17Parkinson Disease 4, Autosomal Dominant Lewy Body 16Esophageal Squamous Cell Carcinoma 16Adenocarcinoma of Lung 16Fallopian Tube Neoplasms 14Carcinoma, Squamous Cell 14Adenocarcinoma 12Melanoma 11Inflammatory Breast Neoplasms 11Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Salivary Gland Neoplasms 8Endometrial Neoplasms 8

Interventions

radium Ra 223 dichloride 1atezolizumab 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Castrate-Resistant Prostate Cancer × Docetaxel × Clear all
NCT01234025 2023-10-06

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Ionis Pharmaceuticals, Inc.

Phase 1/2 Completed
113 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡